{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:09:00Z","timestamp":1783152540667,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40263-015-0286-3","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T06:13:04Z","timestamp":1445926384000},"page":"879-891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database"],"prefix":"10.1007","volume":"29","author":[{"given":"Mauro","family":"Melis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sm\u00e5brekke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Buccellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vaccheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Motola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,27]]},"reference":[{"issue":"1","key":"286_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/81.1.93","volume":"81","author":"K Astrom","year":"1958","unstructured":"Astrom K, Mancall E, Richardson E. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin\u2019s disease. Brain. 1958;81(1):93\u2013111.","journal-title":"Brain."},{"issue":"7712","key":"286_CR2","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","volume":"1","author":"BL Padgett","year":"1971","unstructured":"Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1(7712):1257\u201360.","journal-title":"Lancet."},{"key":"286_CR3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1590\/0004-282X20130154","volume":"71","author":"MA Lima","year":"2013","unstructured":"Lima MA. Progressive multifocal leukoencephalopathy: new concepts. Arq Neuropsiquiatr. 2013;71:699\u2013702.","journal-title":"Arq Neuropsiquiatr."},{"key":"286_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3949\/ccjm.78.s2.02","volume":"78","author":"EO Major","year":"2011","unstructured":"Major EO. History and current concepts in the pathogenesis of PML. Cleve Clin J Med. 2011;78:3\u20137.","journal-title":"Cleve Clin J Med."},{"key":"286_CR5","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1469-0691.2011.03653.x","volume":"17","author":"E Tavazzi","year":"2011","unstructured":"Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect. 2011;17:1776\u201380.","journal-title":"Clin Microbiol Infect."},{"key":"286_CR6","doi-asserted-by":"crossref","unstructured":"Brand\u00e3o M, Dam\u00e1sio J, Marinho A, Silva AM, Vasconcelos J, Neves E, et al. Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia. Clin Rev Allergy Immunol. 2012;43(3):302\u20137.","DOI":"10.1007\/s12016-012-8327-x"},{"key":"286_CR7","doi-asserted-by":"crossref","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 2009;10(8):816\u201324 (Elsevier Ltd).","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"286_CR8","doi-asserted-by":"crossref","first-page":"839719","DOI":"10.1155\/2013\/839719","volume":"2013","author":"A Bellizzi","year":"2013","unstructured":"Bellizzi A, Anzivino E, Rodio DM, Palamara AT, Nencioni L, Pietropaolo V. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol. 2013;2013:839719.","journal-title":"Clin Dev Immunol."},{"key":"286_CR9","doi-asserted-by":"crossref","unstructured":"D\u2019Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55(3):320\u20138.","DOI":"10.1002\/ana.10827"},{"issue":"4","key":"286_CR10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S0317167100012105","volume":"38","author":"DL Keene","year":"2011","unstructured":"Keene DL, Legare C, Taylor E, Gallivan J, Cawthorn GM, Vu D. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci. 2011;38(4):565\u201371.","journal-title":"Can J Neurol Sci"},{"issue":"January","key":"286_CR11","first-page":"1","volume":"5","author":"C Antoniol","year":"2015","unstructured":"Antoniol C, Stankoff B. Immunological markers for PML prediction in MS patients treated with natalizumab. Front Immunol. 2015;5(January):1\u20139.","journal-title":"Front Immunol."},{"issue":"7","key":"286_CR12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","volume":"71","author":"BK Kleinschmidt-DeMasters","year":"2012","unstructured":"Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012;71(7):604\u201317.","journal-title":"J Neuropathol Exp Neurol."},{"key":"286_CR13","unstructured":"European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). EMA. 2012. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129138.pdf . Accessed 19 Oct 2015."},{"key":"286_CR14","unstructured":"Uppsala Monitoring Centre (UMC). VigiBase. Available from: http:\/\/www.who-umc.org\/ . Accessed 19 Oct 2015."},{"key":"286_CR15","unstructured":"World Health Organization (WHO), Collaborating Centre for Drug Statistics Methodology. ATC\/DDD index 2014. WHO. 2014. Available from: http:\/\/www.whocc.no\/atc_ddd_index\/ . Accessed 4 Nov 2015."},{"issue":"April","key":"286_CR16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(April):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"5","key":"286_CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","volume":"26","author":"E Puijenbroek Van","year":"2003","unstructured":"Van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf. 2003;26(5):293\u2013301.","journal-title":"Drug Saf."},{"key":"286_CR18","unstructured":"European Medicines Agency (EMA). Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/includes\/medicines\/medicines_landing_page.jsp&mid= . Accessed 19 Oct 2015."},{"key":"286_CR19","unstructured":"US Food and Drug Administration [FDA]. Accessdata.fda.gov. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/ . Accessed 19 Oct 2015."},{"key":"286_CR20","unstructured":"Electronic Medicines Compendium (EMC). Available from: https:\/\/www.medicines.org.uk\/emc\/ . Accessed 19 Oct 2015."},{"issue":"11","key":"286_CR21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/pds.3320","volume":"21","author":"N Schmedt","year":"2012","unstructured":"Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2012;21(11):1216\u201320.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"286_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pds.3414","volume":"22","author":"C Piccinni","year":"2013","unstructured":"Piccinni C, Sacripanti C, Poluzzi E, De Ponti F. Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants. Pharmacoepidemiol Drug Saf. 2013;22(4):443\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"286_CR23","unstructured":"US Food and Drug Administration (FDA). DrugCite. Available from: http:\/\/www.drugcite.com\/ . Accessed 19 Oct 2015."},{"key":"286_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/892047","volume":"2015","author":"MA Lane","year":"2015","unstructured":"Lane MA, Renga V, Pachner AR, Cohen JA. Late occurrence of PML in a patient treated for lymphoma with immunomodulatory chemotherapies, bendamustine, rituximab, and ibritumomab tiuxetan. Case Rep Neurol Med. 2015;2015:1\u20134.","journal-title":"Case Rep Neurol Med."},{"key":"286_CR25","unstructured":"US Food and Drug Administration [FDA]. FDA drug safety communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate). FDA. 2014. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM424634.pdf . Accessed 19 Oct 2015."},{"key":"286_CR26","unstructured":"Biogen Idec, Inc. Tecfidera NDA 204063\/S-003, S-008, S-010: FDA approved labeling text 12\/3\/14. US Food and Drug Administration, 2014. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204063s003s008s010lbl.pdf . Cited 22 Apr 2015."},{"issue":"17","key":"286_CR27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","volume":"368","author":"U Ermis","year":"2013","unstructured":"Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657\u20138.","journal-title":"N Engl J Med."},{"issue":"15","key":"286_CR28","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMc1413724","volume":"372","author":"DJ Nieuwkamp","year":"2015","unstructured":"Nieuwkamp DJ, Murk J-L, Cremers CHP, Killestein J, Viveen MC, Van Hecke W, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015;372(15):1474\u20136.","journal-title":"N Engl J Med."},{"issue":"15","key":"286_CR29","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","volume":"372","author":"T Rosenkranz","year":"2015","unstructured":"Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 2015;372(15):1476\u20138.","journal-title":"N Engl J Med."},{"issue":"11","key":"286_CR30","first-page":"1363","volume":"65","author":"M Takao","year":"2013","unstructured":"Takao M. Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies. Brain Nerve. 2013;65(11):1363\u201374.","journal-title":"Brain Nerve."},{"issue":"3","key":"286_CR31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25(3):471\u2013506.","journal-title":"Clin Microbiol Rev."},{"key":"286_CR32","first-page":"25","volume":"5","author":"R Planas","year":"2014","unstructured":"Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing\u2013remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014;5:25\u201333.","journal-title":"Patient Relat Outcome Meas."},{"issue":"7","key":"286_CR33","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/annrheumdis-2013-204978","volume":"73","author":"M Ray","year":"2014","unstructured":"Ray M, Curtis JR, Baddley JW. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis. 2014;73(7):1429\u201331.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"286_CR34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","volume":"369","author":"R Wathes","year":"2013","unstructured":"Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369(2):197\u20138.","journal-title":"N Engl J Med."},{"issue":"11","key":"286_CR35","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/art.27687","volume":"62","author":"D Kumar","year":"2010","unstructured":"Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 2010;62(11):3191\u20135.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"286_CR36","first-page":"1018","volume":"33","author":"J Jarand","year":"2006","unstructured":"Jarand J, Zochodne DW, Martin LO, Voll C. Neurological complications of infliximab. J Rheumatol. 2006;33(5):1018\u201320.","journal-title":"J Rheumatol."},{"issue":"Suppl","key":"286_CR37","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/344280","volume":"186","author":"BF Sabath","year":"2002","unstructured":"Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(Suppl):S180\u20136.","journal-title":"J Infect Dis."},{"issue":"12","key":"286_CR38","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761\u20135.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"286_CR39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-012-1321-7","volume":"69","author":"C Biagi","year":"2013","unstructured":"Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69(2):237\u201344.","journal-title":"Eur J Clin Pharmacol."},{"issue":"7","key":"286_CR40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00002018-200831070-00006","volume":"31","author":"D Motola","year":"2008","unstructured":"Motola D, Vargiu A, Leone R, Conforti A, Mretti U, Vaccheri A, et al. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf. 2008;31(7):609\u201316.","journal-title":"Drug Saf."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0286-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0286-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0286-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:25Z","timestamp":1559490085000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0286-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0286-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}